JOHN KIRKWOOD to CD8-Positive T-Lymphocytes
This is a "connection" page, showing publications JOHN KIRKWOOD has written about CD8-Positive T-Lymphocytes.
Connection Strength
2.816
-
Assessing clonal changes in T?cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024 Sep 09; 42(9):1491-1493.
Score: 0.776
-
LAG-3 and PD-1 synergize on CD8+ T?cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell. 2024 Aug 08; 187(16):4355-4372.e22.
Score: 0.193
-
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024 Aug 08; 187(16):4373-4388.e15.
Score: 0.193
-
Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. Oncologist. 2024 Jul 05; 29(7):619-628.
Score: 0.192
-
Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020 12; 17(12):721-722.
Score: 0.149
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
Score: 0.145
-
Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020 01 09; 10(1):92.
Score: 0.140
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
Score: 0.134
-
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015 Apr 15; 75(8):1635-44.
Score: 0.100
-
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
Score: 0.092
-
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012 Aug 15; 131(4):874-84.
Score: 0.081
-
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27; 207(10):2175-86.
Score: 0.073
-
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010 Jul-Aug; 33(6):630-8.
Score: 0.073
-
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009 Nov 15; 15(22):7036-44.
Score: 0.069
-
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
Score: 0.067
-
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
Score: 0.064
-
Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res. 2006 Apr; 16(2):165-74.
Score: 0.054
-
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022 12 01; 28(23):5030-5039.
Score: 0.043
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
Score: 0.038
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.038
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
Score: 0.037
-
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020 10 15; 26(20):5520-5533.
Score: 0.036
-
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
Score: 0.029